Scarica l'app Stockscreener
1.76
0.00%
0.00
Dopo l'orario di chiusura:
1.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.76
Aprire:
$1.74
Volume 24 ore:
1.15M
Relative Volume:
0.58
Capitalizzazione di mercato:
$263.07M
Reddito:
$257.24M
Utile/perdita netta:
$-237.89M
Rapporto P/E:
-0.6769
EPS:
-2.6
Flusso di cassa netto:
$-175.17M
1 W Prestazione:
+4.14%
1M Prestazione:
-15.79%
6M Prestazione:
+36.43%
1 anno Prestazione:
+70.87%
Intervallo 1D:
$1.74
$1.8262
Intervallo di 1 settimana:
$1.57
$1.8262
Portata 52W:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.76 | 263.07M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Oppenheimer | Outperform |
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat
CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider
Hepatocellular Carcinoma Clinical Trial Pipeline Shows - openPR.com
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha
Coherus Oncology announces proposed public offering of common stock - MSN
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) - Yahoo Finance
Coherus closes $50.1 million public offering of common stock By Investing.com - Investing.com Australia
Coherus closes $50.1 million public offering of common stock - Investing.com India
Coherus Biosciences Completes $47 Million Equity Offering - TipRanks
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - The Manila Times
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan
Coherus Oncology (NASDAQ: CHRS) raises $47M through common stock offering - Stock Titan
More drugmakers are turning to cancer combos. Will it help patients live longer? - PharmaVoice
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts - MarketBeat
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com Canada
Coherus BioSciences stock falls after pricing $50.1 million share offering By Investing.com - Investing.com Australia
CHRS Should I Buy - Intellectia AI
CHRS Successfully Completes Joint Book-Running Offering - GuruFocus
Coherus Oncology prices stock offering to raise $50.1M - MSN
Latham & Watkins Advises Coherus Oncology on Public Offering of Common Stock - Latham & Watkins LLP
Coherus Oncology’s Stock Offering: Strategic Moves Unveiled - timothysykes.com
Coherus BioSciences stock falls after pricing $50.1 million share offering - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Coherus Oncology tumbles on $50 mln stock sale - TradingView
Coherus Prices $50.1 Mln Public Offering; Stock Plunges - RTTNews
Coherus Oncology (CHRS) Launches $50.1M Public Offering - GuruFocus
Coherus BioSciences Prices $50.1 Million Share Offering - marketscreener.com
Coherus BioSciences (CHRS) Announces Public Stock Offering - GuruFocus
Coherus Oncology prices $50.1 million public offering of common stock - Investing.com
Coherus Oncology Prices Public Offering at $1.75 per Share - Intellectia AI
Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan
Coherus Oncology announces pricing of public offering of common stock - marketscreener.com
Coherus Oncology Announces Pricing Of Public Offering Of Common Stock - TradingView
Press Release: Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - 富途牛牛
Coherus Oncology tumbles on planned equity offering - TradingView
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):